Vibalogics Completes Virotherapy Facility

Vibalogics completed construction in December of 2021 on a $150 million virotherapy facility in Boxborough, Mass. Sited on 145 acres, the next-generation manufacturing plant supports commercial production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products. The highly flexible structure incorporates 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control.

The leased project involved the partial demolition and renovation of an existing R&D building owned by Lincoln Property Company. Cardinal Group was the construction manager with DPS providing laboratory design and engineering services. Germfree supplied turnkey modular cleanrooms that meet the Centers for Disease Control and Prevention's guidelines for Biosafety Level 2 Large Scale (BSL-2LS). By leveraging offsite construction methodology, the facility was completed in just 13 months.